DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Micardis (Telmisartan) - Summary

 
 



USE IN PREGNANCY
When used in pregnancy during the second and third trimesters, drugs that act directly on the renin-angiotensin system can cause injury and even death to the developing fetus.
When pregnancy is detected, MICARDIS tablets should be discontinued as soon as possible.
See WARNINGS: Fetal/Neonatal Morbidity and Mortality

 

MICARDIS SUMMARY

MICARDIS® (telmisartan) is a nonpeptide angiotensin II receptor (type AT1) antagonist.

MICARDIS (telmisartan) is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.
See all Micardis indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Micardis (Telmisartan)

CDC study shows higher rates of hypertension among adults with disabilities
Source: Cardiovascular / Cardiology News From Medical News Today [2014.08.15]
CDC researchers report that adults with disabilities had higher rates of hypertension compared to adults without disabilities.

Study examines midlife hypertension and cognitive change over 20-year period
Source: Hypertension News From Medical News Today [2014.08.05]
Hypertension in middle age (48 to 67 years) was associated with a greater, although still a modest, decline in cognition over a 20-year period compared with individuals who had normal blood...

Gis map details program aimed at increasing hypertension education using barbershops
Source: Hypertension News From Medical News Today [2014.07.24]
Heart disease and stroke are the second and fourth leading causes of death among black men in the Mississippi Delta region.

Screening for undiagnosed hypertension via electronic health records
Source: IT / Internet / E-mail News From Medical News Today [2014.07.20]
A new study authored by Northwestern Medicine® researchers found that reviewing electronic health records (EHRs) using algorithms can successfully identify patients with previously undiagnosed...

Risk of hypertension increased in pregnancies resulting from egg donation
Source: Fertility News From Medical News Today [2014.07.02]
With an ever-ageing female patient population, egg donation is an increasingly common treatment in infertility.

more news >>

Published Studies Related to Micardis (Telmisartan)

Effects of telmisartan and losartan on cardiovascular protection in Japanese hypertensive patients. [2011.11]
The Telmisartan and Losartan Cardiac Evaluation Trial, a multicenter, prospective, randomized, open-labeled, blinded-endpoint trial, was designed to compare the effects of two angiotensin II receptor blockers (ARBs), telmisartan and losartan, on cardiovascular protection in Japanese patients with mild to moderate essential hypertension...

High-dose treatment with telmisartan induces monocytic peroxisome proliferator-activated receptor-gamma target genes in patients with the metabolic syndrome. [2011.10]
The present study aimed to explore the anti-inflammatory effects and peroxisome proliferator-activated receptor-gamma (PPARgamma)-activating properties of the angiotensin type 1 receptor blocker telmisartan by analysis of serum interleukin 6 levels and monocytic PPARgamma target gene expression in drug-naive patients with the metabolic syndrome...

Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies. [2011.03.15]
CONCLUSIONS: This post hoc analysis does not support dual therapy over monotherapy in high-vascular risk patients with low glomerular filtration rate or albuminuria. This observation is a post hoc comparison and should be interpreted appropriately. CLINICAL TRIAL REGISTRATION: URL: http://clinicaltrials.gov Identifier: NCT00153101.

Blood pressure control by the nifedipine GITS-telmisartan combination in patients at high cardiovascular risk: the TALENT study. [2011.03]
BACKGROUND: Guidelines on hypertension regard combinations between two antihypertensive drugs to be the most important treatment strategy. Because of the complementary mechanism of action and the evidence of cardiovascular protective effects they include the combination of a calcium antagonist and an angiotensin receptor antagonist among the priorital ones to employ. AIMS: To determine in hypertensive patients at high cardiovascular risk whether combining Nifedipine GITS at low dose and telmisartan reduced ambulatory and clinic blood pressure (BP) more than the combination components, controlled BP early after treatment initiation and allowed to also obtain a better long-term BP control compared to initiating treatment with the combination components and moving to the combination later... CONCLUSION: Combination treatment with nifedipine GITS low dose and telmisartan provides a greater and earlier clinic and ambulatory BP reduction than the combination components in monotherapy. Initiating treatment with the combination did not result in any better longer term BP control compared to starting treatment with monotherapy and moving to the combination later.

Differential effect of telmisartan and amlodipine on monocyte chemoattractant protein-1 and peroxisome proliferator-activated receptor-gamma gene expression in peripheral monocytes in patients with essential hypertension. [2011.01]
Monocyte chemoattractant protein-1 (MCP-1) and peroxisome proliferator-activated receptor-gamma (PPAR-gamma) play a significant role in monocyte activation, vascular inflammation, and atherogenesis. Angiotensin receptor blockers and calcium channel blockers are antihypertensive drugs with established efficacy and a favorable safety profile...

more studies >>

Clinical Trials Related to Micardis (Telmisartan)

Telmisartan80mg/hydrochlothiazide12.5mg (Micardis Plus) ABPM Study in China [Completed]
to evaluate the trough and peak effect of once daily MICARDIS PLUS? (Telmisartan 80mg / hydrochlorot hiazide 12. 5 mg) by 24 ABPM in patients with mild to moderate essential hypertension

INNOVATION Study - Telmisartan (Micardis?) in Incipient Diabetic Nephropathy [Completed]
The aim of this study is to compare the preventive effect of Telmisartan (Micardis?) versus placebo control on the transition to overt nephropathy in patients with diabetic nephropathy manifesting mic roalbuminuria associated with type II diabetes, and to evaluate the efficacy and safety of Telmisart an (Micardis?, Gliosartan?, Kinzal?, Kinzalmono?, Predxal?, Pritor?, Samertan?, Telmisartan?) for di abetic nephropathy patients.

PRO-POWER: Hypertension With Risk Factors for a Duration of 24 Weeks With Micardis 80mg/Micardis Plus 80mg/12.5mg [Recruiting]
PRO-POWER is an observational cohort study for a period of 24 weeks. All recruited patients will have essential hypertension. In addition, the patients will have at least one other contributing risk factor for cardiovascular events. The study aims to evaluate the safety, efficacy and protection of Micardis 80mg/Micardis plus 80/12. 5mg from cardiovascular risks in patients with essential hypertension

CKD-828 Telmisartan Non-Responder Trial [Recruiting]
The aim of the present study is to evaluate the efficacy and safety of two dose combination of Telmisartan/S-Amlodipine (40/2. 5mg and 40/5mg) compared with telmisartan monotherapy (80mg) in hypertensive patients inadequately controlled by telmisartan monotherapy.

Telmisartan80/HCTZ25 Versus telmisartan80/HCTZ12.5 in Hypertension Not Responding to telmisartan80/HCTZ12.5 [Completed]
The primary objective of this trial is to demonstrate that a fixed dose combination of telmisartan 8 0 mg plus hydrochlorothiazide 25 mg (T80/H25) is superior in reducing blood pressure after eight wee ks compared with a fixed dose combination of telmisartan 80 mg plus hydrochlorothiazide 12. 5 mg (T80

/H12. 5) in patients who fail to respond to six weeks treatment with T80/H12. 5.

more trials >>

Reports of Suspected Micardis (Telmisartan) Side Effects

Dizziness (27)Interstitial Lung Disease (23)Blood Pressure Increased (17)Renal Impairment (17)Hypertension (17)Drug Ineffective (14)Malaise (13)Nausea (13)Headache (12)Dyspepsia (12)more >>


PATIENT REVIEWS / RATINGS / COMMENTS

Based on a total of 4 ratings/reviews, Micardis has an overall score of 5. The effectiveness score is 7 and the side effect score is 6.50. The scores are on ten point scale: 10 - best, 1 - worst. Below are selected reviews: the highest, the median and the lowest rated.
 

Micardis review by 55 year old female patient

  Rating
Overall rating:  
Effectiveness:   Considerably Effective
Side effects:   No Side Effects
  
Treatment Info
Condition / reason:   hypertension
Dosage & duration:   40 mg taken daily for the period of ongoing, for six months
Other conditions:   diabetes type 2, depression/anxiety
Other drugs taken:   metformin hydrochloride, venlafaxine hydrochloride
  
Reported Results
Benefits:   reduced blood pressure to within acceptable limits. replaced previous drug (ACE inhibitor) with undesirable side effects.
Side effects:   none noticed
Comments:   one tablet daily, in the morning.

 

Micardis review by 51 year old male patient

  Rating
Overall rating:  
Effectiveness:   Considerably Effective
Side effects:   Severe Side Effects
  
Treatment Info
Condition / reason:   high blood pressure
Dosage & duration:   80mg a day taken 5 months for the period of 5 months
Other conditions:   None
Other drugs taken:   None
  
Reported Results
Benefits:   Reduced blood pressure. Since takink telmisartan my blood pressure levels went down to normal. I could do my regular activities, including sports.
Side effects:   Reduced sex drive, erectile disfunction. Constant respiratory infection. Since taking telmisartan i have been constantly with intense colds and respiratory tract infections. Plus my sexual drive has reduced considerably. I am not interested in sex and when I had to have sexual relations i experienced difficulty maintaining an erection.
Comments:   Only medication was prescribed. temisartan 80 mg a day. I have benn taking it for more than 5 months.

 

Micardis review by 51 year old male patient

  Rating
Overall rating:  
Effectiveness:   Considerably Effective
Side effects:   Severe Side Effects
  
Treatment Info
Condition / reason:   high blood pressure
Dosage & duration:   80mg a day taken 5 months for the period of 5 months
Other conditions:   None
Other drugs taken:   None
  
Reported Results
Benefits:   Reduced blood pressure. Since takink telmisartan my blood pressure levels went down to normal. I could do my regular activities, including sports.
Side effects:   Reduced sex drive, erectile disfunction. Constant respiratory infection. Since taking telmisartan i have been constantly with intense colds and respiratory tract infections. Plus my sexual drive has reduced considerably. I am not interested in sex and when I had to have sexual relations i experienced difficulty maintaining an erection.
Comments:   Only medication was prescribed. temisartan 80 mg a day. I have benn taking it for more than 5 months.

See all Micardis reviews / ratings >>

Page last updated: 2014-08-15

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014